专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明公开

EP2281557A2 PHARMACEUTICAL FORMULATION CONTAINING ANGIOTENSIN-II RECEPTOR BLOCKER 审中-公开
标题翻译： EINEN ANGIOTENSIN-II-REZEPTORBLOCKER ENTHALTENDE PHARMAZEUTISCHE FORMULIERUNG
公开(公告)号：EP2281557A2
公开(公告)日：2011-02-09
申请号：EP09738963.9
申请日：2009-04-28
申请人： HanAll Biopharma Co., Ltd.
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , LEE, Ah Ram , SON, Jae Woon , KIM, Jeong Taek
IPC分类号： A61K9/22 , A61K9/00 , A61K9/20 , A61K9/48
CPC分类号： A61K31/00 , A61K9/2081 , A61K9/2866 , A61K31/41 , A61K31/4178
摘要： The present invention provides a pharmaceutical formulation containing an angiotensin-II receptor blocker and a release-control material as a pharmacologically active ingredient and a pharmaceutical formulation comprising an immediate-release compartment and an extended-release compartment. The immediate-release compartment contains an agent as a pharmacologically active ingredient for preventing and inhibiting hepatitis and the extended-release compartment has an angiotensin-II receptor blocker as a pharmacologically active ingredient. The formulation of the present invention maximizes the effectiveness on pharmacologically and clinically lowering blood pressure and preventing complications when taking the formulation, helps to avoid interaction with a drug which is metabolized by the same enzyme in the liver, and prevents and inhibits the incidence of drug-induced hepatitis which is caused by drug administration for a long time.
摘要翻译：本发明提供含有血管紧张素-II受体阻断剂和作为药理活性成分的释放控制材料的药物制剂以及包含立即释放室和延长释放室的药物制剂。立即释放隔室含有作为预防和抑制肝炎的药理活性成分的药剂，并且延长释放室具有作为药理活性成分的血管紧张素-II受体阻断剂。本发明的制剂使药物和临床上降低血压的效果最大化，并且在服用制剂时预防并发症，有助于避免与由肝脏中相同的酶代谢的药物相互作用，并且预防和抑制药物的发生引起的药物长期引起的肝炎。

2. 发明授权

EP2109447B1 N, N- DIMETHYL IMIDODICARBONIMIDIC DIAMIDE ACETATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 失效转让
标题翻译： N，N-二甲基IMIDODICARBONIMID-DIAMID®醋酸酯，方法才能产生与药物组合物
公开(公告)号：EP2109447B1
公开(公告)日：2015-06-10
申请号：EP08712220.6
申请日：2008-01-29
申请人： HanAll Biopharma Co., Ltd.
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong
IPC分类号： A61K31/155 , A61P3/08 , C07C279/26
CPC分类号： A61K31/155 , C07C279/26

3. 发明公开

EP2255797A2 COMPOSITE PREPARATION 审中-公开
标题翻译： KOMPOSIT-HERSTELLUNG
公开(公告)号：EP2255797A2
公开(公告)日：2010-12-01
申请号：EP09713514.9
申请日：2009-02-21
申请人： HanAll Biopharma Co., Ltd.
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SUN, Sang Ouk , BAE, Jung-won
IPC分类号： A61K9/52 , A61K9/00 , A61K9/20 , A61K9/22 , A61K47/00
CPC分类号： A61K9/2077 , A61K9/2009 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2059 , A61K9/2081 , A61K9/209 , A61K9/2866 , A61K9/4808 , A61K9/5078 , A61K9/5084 , A61K31/4365 , A61K31/60 , A61K31/616 , A61K2300/00
摘要： The present invention provides a combination preparation which comprises: a prior-release section comprising aspirin or a pharmaceutically acceptable salt thereof as a pharmacologically active component; and a delayed-release section comprising clopidogrel, an isomer thereof or a pharmaceutically acceptable salt thereof as a pharmacologically active component. The combination preparation of the present invention exhibits a far better effect in preventing platelet aggregation than does simultaneous oral therapy or treatment with the respective single preparations, and not only can it improve the patient's drug-taking compliance by administration once a day but it can also reduce the adverse reactions which follow long-term administration of aspirin. The combination preparation of the present invention is also advantageous in that it exhibits an outstanding effect in inhibiting blood platelet aggregation despite a reduction in the amount of aspirin ingested, and in that it converts clopidogrel resistance into susceptibility and prevents serious adverse reactions caused by clopidogrel resistance and in that it can be stored over the longer term since it is stable under common storage conditions.
摘要翻译：本发明提供了一种组合制剂，其包含：包含阿司匹林或其药学上可接受的盐作为药理活性成分的先前释放部分; 以及包含氯吡格雷，其异构体或其药学上可接受的盐作为药理活性成分的延迟释放部分。本发明的组合制剂与单独使用的制剂同时进行口服治疗或治疗相比，具有更好的预防血小板聚集的效果，并且不仅可以通过一天一次的给药来改善患者的药物依从性，而且还可以减少长期服用阿司匹林后的不良反应。本发明的组合制剂的优点还在于尽管阿司匹林摄入量减少，但其表现出抑制血小板聚集的突出效果，并且将氯吡格雷耐药性转化为易感性并防止由氯吡格雷耐药引起的严重不良反应并且由于它在常见的储存条件下是稳定的，因此可以长期储存。

4. 发明公开

EP2255796A2 PHARMACEUTICAL PREPARATION 审中-公开
标题翻译：药剂师ZUBEREITUNG
公开(公告)号：EP2255796A2
公开(公告)日：2010-12-01
申请号：EP09711817.8
申请日：2009-02-23
申请人： HanAll Biopharma Co., Ltd.
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SON, Jaw Woon , KIM, Jin Wook
IPC分类号： A61K9/52 , A61K9/22 , A61K9/00 , A61K31/165 , A61K31/41 , A61K47/00
CPC分类号： A61K9/209 , A61K9/0004 , A61K31/165 , A61K31/41
摘要： The present invention provides a pharmaceutical preparation including a compartment containing a renin inhibitor as a pharmacologically active ingredient, and a compartment containing an HMG-CoA reductase inhibitor as a pharmacologically active ingredient, wherein one compartment is a prior-release compartment and the other compartment is a delayed-release compartment. The combination preparation of the present invention can deliver a renin inhibitor and an HMG-CoA reductase inhibitor with a time interval at a specific speed, thus reducing undesirable side-effects, improving the drug efficacy and promoting the patient compliance. Further, the pharmaceutical preparation of the present invention has pharmacological, clinical, scientific and economical advantages in the prevention or treatment of metabolic syndromes, cardiovascular diseases, renal diseases and the like, as compared with the complex drug regimens in which medicament ingredients are taken individually or simultaneously.
摘要翻译：本发明提供一种药物制剂，其包含含有作为药理活性成分的肾素抑制剂的隔室，以及含有作为药理活性成分的HMG-CoA还原酶抑制剂的隔室，其中一个隔室为先前释放室，另一隔室为延迟释放隔间。本发明的组合制剂可以以特定速度的时间间隔递送肾素抑制剂和HMG-CoA还原酶抑制剂，从而减少不期望的副作用，改善药物功效并促进患者依从性。此外，与复合药物方案相比，本发明的药物制剂在预防或治疗代谢综合征，心血管疾病，肾脏疾病等方面具有药理学，临床学，科学和经济学优势，其中药物成分单独服用或同时。

5. 发明授权

EP2086519B1 CONTROLLED RELEASE COMPLEX COMPOSITION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKERS AND HMG-COA REDUCTASE INHIBITORS 失效转让
标题翻译：具有血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂COMPLEX控释组合物
公开(公告)号：EP2086519B1
公开(公告)日：2017-06-21
申请号：EP07833713.6
申请日：2007-10-30
申请人： HanAll Biopharma Co., Ltd.
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , SON, Jae Woon
IPC分类号： A61K9/20 , A61K9/24 , A61K31/00
CPC分类号： A61K31/00 , A61K9/2077 , A61K9/209

6. 发明公开

EP2848245A1 BOSENTAN CONTROLLED RELEASE ORAL PREPARATION 审中-公开
标题翻译：口服VERABREICHBARESBOSENTANPRÄPARATMIT GESTEUERTER FREISETZUNG
公开(公告)号：EP2848245A1
公开(公告)日：2015-03-18
申请号：EP13788233.8
申请日：2013-05-10
申请人： Hanall Biopharma Co., Ltd.
发明人： KIM, Sung Wuk , CHOI, Seong Choon , KOO, Ja Seong , SUN, Sang Ouk , LEE, Na Young
IPC分类号： A61K9/22 , A61K9/20 , A61K31/506
CPC分类号： A61K31/506 , A61K9/2027 , A61K9/2031 , A61K9/2054 , A61K9/2077 , A61K9/209 , A61K9/28 , A61K9/2833 , A61K9/284 , A61K9/2846 , A61K9/2853 , A61K9/2866 , A61K9/2886
摘要： Provided are an extended release preparation for oral administration of bosentan including bosentan, a pharmaceutically acceptable salt thereof or a solvate thereof as an active ingredient and a hydrophilic polymer as a sustained release excipient, and a method of manufacturing the same. Accordingly, the number of administrations of the bosentan, a pharmaceutically acceptable salt thereof or a solvate thereof may be reduced, thereby enhancing ease of administration and patient compliance. In addition, the extended release preparation for oral administration of bosentan may be effectively manufactured.
摘要翻译：本发明提供一种用于口服白蛋白，包括波生坦，其药学上可接受的盐或其溶剂化物作为活性成分的延长释放制剂和作为缓释赋形剂的亲水性聚合物及其制备方法。因此，可以减少波生坦，其药学上可接受的盐或其溶剂化物的施用次数，从而增加给药的便利性和患者依从性。此外，可以有效地制造用于口服白蛋白的延长释放制剂。

7. 发明公开

EP2275093A2 PHARMACEUTICAL FORMULATION 审中-公开
标题翻译：药剂师
公开(公告)号：EP2275093A2
公开(公告)日：2011-01-19
申请号：EP09729736.0
申请日：2009-04-08
申请人： HanAll Biopharma Co., Ltd.
发明人： KIM, Sung Wuk , JUN, Sung Soo , KOO, Ja Seong , KIM, Jin Wook , SON, Jae Woon , JO, Young Gwan
IPC分类号： A61K9/22 , A61K31/165 , A61K9/48 , A61K31/41 , A61K31/4196 , A61K31/4178 , A61P9/10
CPC分类号： A61K31/41 , A61K9/0004 , A61K9/1623 , A61K9/1635 , A61K9/1652 , A61K9/2018 , A61K9/2027 , A61K9/2054 , A61K9/2059 , A61K9/2081 , A61K9/209 , A61K9/2866 , A61K9/4808 , A61K9/5015 , A61K9/5026 , A61K9/5042 , A61K9/5047 , A61K9/5078 , A61K9/5084 , A61K31/165 , A61K31/4178 , A61K31/4196 , A61K45/06 , A61K2300/00
摘要： The present invention provides a pharmaceutical formulation comprising a compartment containing a rennin inhibitor as a pharmacologically active ingredient, and a compartment having an angiotensin-II-receptor blocker as a pharmacologically active ingredient. One of the compartments is an immediate-release compartment and the other one is an extended-release compartment. Since the disclosed formulation delivers the rennin inhibitor and angiotensin-II-receptor blocker at a specific delivery rate at a different time. It has an advantage in reducing the concern about side effects, improving drug effects, and simplifying the instructions for use of the drug. In addition, the formulation can pharmacologically, clinically, scientifically, and economically achieve more useful effects than the complex prescription case of taking the ingredients separately or each at once, in preventing and treating metabolic syndrome, cardiovascular disease and renal disease.
摘要翻译：本发明提供了包含含有作为药理活性成分的肾素抑制剂的隔室的药物制剂和具有作为药理活性成分的血管紧张素-II受体阻断剂的隔室。其中一个隔间是立即释放舱，另一个是延长释放舱。由于所公开的制剂在不同时间以特定的递送速率递送肾素抑制剂和血管紧张素-II-受体阻断剂。它有利于减少对副作用的关注，改善药物作用，并简化药物使用说明。另外，与预防和治疗代谢综合征，心血管疾病和肾脏疾病有关的成分单独或同时使用的复杂处方情况，该制剂在药理学，临床上，科学上和经济上都将获得更多的有用效果。

8. 发明授权

EP2203418B1 N,N-DIMETHYL IMIDODICARBONIMIDIC DIAMIDE DICARBOXYLATE, METHOD FOR PRODUCING THE SAME AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME 失效转让
标题翻译： N，N-二甲基咪唑二甲酰亚胺二酰胺二羧酸盐，生产该组合物的方法和包含该组合物的药物组合物
公开(公告)号：EP2203418B1
公开(公告)日：2017-10-25
申请号：EP08832662.4
申请日：2008-09-19
申请人： HanAll Biopharma Co., Ltd.
发明人： KIM, Sung Wuk , JUN, Sung Soo , JO, Young Gwan , KOO, Ja Seong , KIM, Young Woong , KIM, Byoung Ha , KIM, Duck
IPC分类号： C07C279/26 , C07C55/08 , C07C55/12 , C07C55/14 , C07C59/245
CPC分类号： C07C279/26 , C07C55/08 , C07C55/12 , C07C55/14 , C07C59/245

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式